Biogen’s Spinraza Stays Ahead Of Novartis And Roche Challengers In SMA – For Now

Evrysdi Growing Fast

 
• By Andrew McConaghie
  
Spinraza
Spinraza was the first treatment to offer hope to children with SMA, but Zolgensma and Evrysdi are now providing new options. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip